AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04564157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.
Study NCT04564157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.
Study NCT04564157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
Study NCT04564157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
Study NCT04564157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains.~Route of administration: Intravenous infusion.~Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 4 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions.~Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
Study NCT05372185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA Coordinated Anxiety Learning and Management- Substance Use Version
Description: VA Coordinated Anxiety Learning and Management- Substance Use Version (VA CALM-S) is a cognitive behavior therapy (CBT) program that employs computer assistance to empower providers to deliver CBT with high fidelity. The computer program guides both providers and patients in a course of CBT, and in this study the content will focus on using transdiagnostic treatment elements to address co-occurring anxiety and substance use disorders.
Study NCT05372185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Veterans will engage in VA care using the standard procedures of their facility.
Study NCT05678712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Access to CGM data (Dexcom G6)
Description: Acces to CGM data (not blinded CGM)
Study NCT05891769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18Fluorocholine
Description: 18F Fluorocholine 5 mCi ± 20% administered intravenously.
Study NCT05671159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube
Study NCT05671159 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube
Study NCT06099769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: mouth once daily (160 mg/day)
Study NCT06099769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: mouth once daily 300-mg tablet
Study NCT06099769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC
Description: The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle
Study NCT06463665 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Olvimulogene nanivacirepvec
Description: Olvi-Vec is an engineered oncolytic vaccinia virus
Study NCT06463665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olvimulogene nanivacirepvec
Description: Olvi-Vec is an engineered oncolytic vaccinia virus
Study NCT06463665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Platinum chemotherapy: carboplatin or cisplatin
Description: Administered according to local practice.
Study NCT06463665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy: carboplatin or cisplatin
Description: Administered according to local practice.
Study NCT06463665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
Description: Administered according to local practice.
Study NCT06463665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
Description: Administered according to local practice.
Study NCT06463665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
Description: Administered according to local practice.
Study NCT06463665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
Description: Administered according to local practice.
Study NCT06463665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered according to local practice.
Study NCT06463665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Administered according to local practice.
Study NCT06467084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KVD900 75 mg
Description: KVD900 Tablet 75 mg (1 x 75 mg)
Study NCT06467084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KVD900 150 mg
Description: KVD900 Tablet 150 mg (2 x 75 mg)
Study NCT06467084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KVD900 300 mg
Description: KVD900 Tablet 300 mg (1 x 300 mg)
Study NCT05030038 — intervention group
Intervention type: BIOLOGICAL
Intervention: Fecal swab collection
Description: Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
Study NCT05030038 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
Study NCT05736744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSO4
Description: The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
Study NCT05736744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cis-Atracurium
Description: Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
Study NCT05736744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cis-Atracurium
Description: Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
Study NCT05550207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-07 (meloxicam-rizatriptan)
Description: AXS-07 tablets, taken orally for the acute treatment of migraine
Study NCT05336344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENCODE
Description: a cognitive behavioral intervention for family caregivers to improve pain management skills and overall coping
Study NCT06241118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study NCT06241118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study NCT06241118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Study NCT06241118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Study NCT06241118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus or pimecrolimus
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Study NCT06241118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical tacrolimus or pimecrolimus
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Study NCT05188508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
Study NCT05188508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Olaparib and Temozolomide
Description: Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.
Study NCT06087614 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DE-HyART
Description: The HSV delineation will be done for patients in arm 3 using baseline FMISO. The HSV will be contoured and adjusted according to the second FMISO scan done between the 4th - the 5th week of radiation treatment. A planning CT will also be repeated at the time for adjusting the HSV to account for temporal changes. The Biological Target Volume thus generated after adequate margins will be prescribed 30 Gy in 10 fractions over and above the standard fractination.
Study NCT06087614 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arm
Description: The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.
Study NCT06087614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin injection
Description: Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
Study NCT06087614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
Study NCT06087614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
Study NCT06087614 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard fractionation (Radiation Oncology preference)
Description: Standard institutional practice is detailed before starting the patient. Doses 66-70 Gy over 6-7 weeks
Study NCT06783764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II block and transverse thoracic plane block
Description: will receive a combination of PECS II block and TTPB (injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
Study NCT06783764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: ESPB (30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae)
Study NCT06783764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.25 % injection
Description: injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
Study NCT06783764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.25 % injection
Description: 30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae
Study NCT06786208 — intervention group
Intervention type: DRUG
Intervention: Sunvozertinib
Description: sunvozertinb, a EGFR-TKI, 300mg QD oral
Study NCT06785168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Machine-based Resistance Training
Description: The participants will receive HF treatment as prescribed by cardiologists. If participants have any additional medical conditions, their existing medications or treatments should continue. They are also asked to maintain their usual physical activity, exercise routines, and dietary habits, without making changes outside of the study intervention. At the beginning, patients participating in resistance training should complete a pretest of one-repetition maximum (1-RM) to assess muscle strength, which will be used by a professional physical therapist to develop an individualized prescription. The specific movements are as follows: (1) leg press and (2) calf raise by Proxomed Compass 540 (Germany); (3) leg curl, (4) chest press, (5) push up, (6) seated row by HUR machine (US). During the 8 weeks, subjects will train 3 non-consecutive days/week with intensity 30%1-RM to 60% 1-RM, 3 sets/one excercise with 8-12 repetitions.
Study NCT06786910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste with olive oil, betaine and xylitol
Description: Composition comprising olive oil, betaine and xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
Study NCT06786910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste without olive oil, betaine nor xyitol
Description: Toothpaste without olive oil, without betaine and without xylitol, with identical aspect and flavour to the intervention to use 3 times a day during 1 month.
Study NCT06785181 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Active standing
Description: a session at resting state in supine position, a session during autonomic challenge obtained via active standing evoking reflex sympathetic activation, and a session of emotional elicitation via the administration of videos
Study NCT06781580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esports Ergonomic Protocol
Description: The Esports Ergonomic Protocol is a six-week intervention designed to reduce the risk of repetitive strain injuries and enhance gaming performance for esports athletes. It includes an educational session on ergonomics, focusing on proper posture, body mechanics, and workstation setup. The protocol also incorporates warm-up and cool-down exercises to prevent strain and improve flexibility, as well as a postural rehabilitation program targeting the upper extremities and core muscles.~Participants will attend four in-person sessions at specified intervals for ergonomic risk assessments (using REBA) and gaming performance evaluations (using Kovaaks). The intervention also features online resources, including exercise tutorials and ergonomic tips, to support adherence and long-term implementation. Feedback will be collected through post-intervention surveys and an optional focus group to refine the protocol for future use in the esports community.
Study NCT06784544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Operational Stressors
Description: Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.
Study NCT06784544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operational Stressors
Description: Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.
Study NCT06783829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4394
Description: SHR4394
Study NCT06783972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Touching
Description: In the second stage of birth, when the baby's head crowns, the mother is allowed to touch the baby's head as much as she wants and with as many fingers as she wants.
Study NCT06783504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION
Description: The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.
Study NCT06783504 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION
Description: The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.
Study NCT06782867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Responsive Neurostimulation (RNS)
Description: The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
Study NCT06782672 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular measurements
Description: Measurement of pre-ejection period is the period between the onset of electrical excitation of the left ventricle and the opening of the aortic valve and heart rate will be continuous.~These data will be collected using a cardiograph measuring the ECG signal and impedance cardiography (ICG). The system's four electrodes are positioned on the middle axillary line at the end of the sternum and at the base of the neck.~Blood pressure measurements (PAS and PAD) will be taken from a cuff placed on the brachial artery of the non-dominant arm.~cardiovascular values will be measured continuously:~* Each participant rested while watching a documentary for 8 minutes.~* During two 5-minute memory tasks of different difficulty levels (easy and difficult), separated by a 5-minute break.~The averages of the last 5 minutes during the resting period will constitute the resting values, and the averages of the 5 minutes of each difficulty level will constitute the values during cognitive effort.